NCT05106777 is a Phase 2 clinical trial of Surufatinib in Sarcoma, sponsored by Sun Yat-sen University.

Who is sponsoring NCT05106777?

NCT05106777 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05106777?

Interventions in NCT05106777: Surufatinib.

Is NCT05106777 still recruiting?

NCT05106777 is currently status unknown. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05106777

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Status unknown Phase 2 Last updated 12 April 2023

What this trial tests

Phase 2 trial testing Surufatinib in Sarcoma in 47 participants. Status unknown.

Timeline

10 December 2021

Primary endpoint
10 December 2023

10 December 2023

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	10 December 2021
Primary completion	10 December 2023
Estimated completion	10 December 2023
Sites	1 location across China

Drugs / interventions tested

Surufatinib — full drug profile →

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 14 to 70, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK, Yamamichi T, Yustein JT. · · 2023 · cited 32× · PMID 37511127 · DOI 10.3390/ijms241411367
Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy.
Wang J, Shi K. · · 2025 · PMID 41383602 · DOI 10.3389/fimmu.2025.1658358
MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.
Al Jarroudi O, El Bairi K, Brahmi SA, Afqir S. · · 2025 · PMID 40909947 · DOI 10.3389/fonc.2025.1418537

Verify or expand the search:

Other trials of Surufatinib

Trials testing the same drug.

NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors · Phase 2 · recruiting
NCT07086456 — Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal · Phase 2 · recruiting
NCT06531291 — Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Ne · Phase 2 · not yet recruiting

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05106777 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05106777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing